Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The
acute efficacy of ketamine in TRD has been demonstrated in replicated randomised …

Ketamine has rapid yet often transient antidepressant effects in patients with treatment-
resistant depression. Different strategies have been proposed to prolong these effects …

Objective: Subanesthetic ketamine doses have been shown to have rapid yet transient
antidepressant effects in patients with treatment-resistant depression, which may be …

Introduction Interest in the use of psychedelic substances for the treatment of mental
disorders is increasing. Processes that may affect therapeutic change are not yet fully …

Objectif: Les patients souffrant de trouble dépressif majeur (TDM) ont souvent une réponse
limitée aux médicaments de première et de deuxième intention, donc de nouveaux …

Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine
(Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment …

Introduction: Ketamine has emerged as a rapid-acting antidepressant. While ongoing
treatment can prevent relapse, concerns exist regarding long-term exposure. Objective: We …

Ketamine is an open channel blocker of ionotropic glutamatergic N-Methyl-D-Aspartate
(NMDA) receptors. The discovery of its rapid antidepressant effects in patients with …

Objective Suicide is a major cause of death in adolescents with limited treatment options.
Ketamine and its enantiomers have shown rapid anti-suicidal effects in adults with major …

Background Outcomes of ketamine intravenous therapy (KIT) for depression in real-world
care settings have been minimally evaluated. We set out to quantify treatment response to …